Publications 2019

Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM (2019)
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Thromb Res, 177, 154-156
DOI 10.1016/j.thromres.2019.03.010, PubMed 30903875

Publications 2018

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM (2018)
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
Platelets, 31 (1), 43-47
DOI 10.1080/09537104.2018.1557618, PubMed 30569801

Schultz NH, Lundblad R, Holme PA (2018)
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
J Med Case Rep, 12 (1), 138
DOI 10.1186/s13256-018-1660-9, PubMed 29764497

Publications 2017

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
Res Pract Thromb Haemost, 1 (1), 49-56
DOI 10.1002/rth2.12015, PubMed 30046673

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Thromb J, 15, 6
DOI 10.1186/s12959-017-0129-1, PubMed 28239301